United States: Recent Adalimumab Biosimilar Developments - Goodwin Procter LLP

FDA grants interchangeable designation to Pfizer's adaliumumab biosimilar – On October 5, 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has designated ABRILADA...